drugset / Trial / NCT04449276
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
RandomizedSequentialSingle-blindPrevention
Summary
This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of CVnCoV at different dose levels.
Timeline
- Start
- 2020-06-18
- Primary completion
- 2021-12-21
- Completion
- 2021-12-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 2 ug | Intramuscular |
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 4 ug | Intramuscular |
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 6 ug | Intramuscular |
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 8 ug | Intramuscular |
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 12 ug | Intramuscular |
| Subject | ZORECIMERAN | Messenger RNA (mRNA) | 20 ug | Intramuscular |